TY - JOUR
T1 - Case definition of chronic pulmonary aspergillosis in resource-constrained settings
AU - Denning, David W.
AU - Page, Iain D.
AU - Chakaya, Jeremiah
AU - Jabeen, Kauser
AU - Jude, Cecilia M.
AU - Cornet, Muriel
AU - Alastruey-Izquierdo, Ana
AU - Bongomin, Felix
AU - Bowyer, Paul
AU - Chakrabarti, Arunaloke
AU - Gago, Sara
AU - Guto, John
AU - Hochhegger, Bruno
AU - Hoenigl, Martin
AU - Irfan, Muhammad
AU - Irurhe, Nicholas
AU - Izumikawa, Koichi
AU - Kirenga, Bruce
AU - Manduku, Veronica
AU - Moazam, Samihah
AU - Oladele, Rita O.
AU - Richardson, Malcolm D.
AU - Rodriguez Tudela, Juan Luis
AU - Rozaliyani, Anna
AU - Salzer, Helmut J.F.
AU - Sawyer, Richard
AU - Simukulwa, Nasilele F.
AU - Skrahina, Alena
AU - Sriruttan, Charlotte
AU - Wilopo, Bayu A.P.
AU - Cole, Donald C.
AU - Getahun, Haileyesus
AU - SETIANINGRUM, FINDRA
N1 - Funding Information:
The workshop was funded by the Global Action Fund for Fungal Infections. Contributions toward the workshop were received from the European Confederation for Medical Mycology, European Society for Clinical Microbiology and Infectious Diseases, the International Society for Human and Animal Mycology, Miravista Diagnostics, Immy Inc., Pfizer Inc., Basliea Pharmaceutica, Gilead Sciences, Merck Inc., Cidara Therapeutics Inc., Viamet Pharmaceuticals, F2G Ltd., Pulmocide Ltd., and Scynexis Inc. Some workshop expenses were covered by the National Aspergillosis Centre, University Hospital of South Manchester.
Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Chronic pulmonary aspergillosis (CPA) is a recognized complication of pulmonary tuberculosis (TB). In 2015, the World Health Organization reported 2.2 million new cases of nonbacteriologically confirmed pulmonary TB; some of these patients probably had undiagnosed CPA. In October 2016, the Global Action Fund for Fungal Infections convened an international expert panel to develop a case definition of CPA for resource-constrained settings. This panel defined CPA as illness for >3 months and all of the following: 1) weight loss, persistent cough, and/or hemoptysis; 2) chest images showing progressive cavitary infiltrates and/or a fungal ball and/or pericavitary fibrosis or infiltrates or pleural thickening; and 3) a positive Aspergillus IgG assay result or other evidence of Aspergillus infection. The proposed definition will facilitate advancements in research, practice, and policy in lower-and middle-income countries as well as in resource-constrained settings.
AB - Chronic pulmonary aspergillosis (CPA) is a recognized complication of pulmonary tuberculosis (TB). In 2015, the World Health Organization reported 2.2 million new cases of nonbacteriologically confirmed pulmonary TB; some of these patients probably had undiagnosed CPA. In October 2016, the Global Action Fund for Fungal Infections convened an international expert panel to develop a case definition of CPA for resource-constrained settings. This panel defined CPA as illness for >3 months and all of the following: 1) weight loss, persistent cough, and/or hemoptysis; 2) chest images showing progressive cavitary infiltrates and/or a fungal ball and/or pericavitary fibrosis or infiltrates or pleural thickening; and 3) a positive Aspergillus IgG assay result or other evidence of Aspergillus infection. The proposed definition will facilitate advancements in research, practice, and policy in lower-and middle-income countries as well as in resource-constrained settings.
UR - http://www.scopus.com/inward/record.url?scp=85050384089&partnerID=8YFLogxK
U2 - 10.3201/eid2408.171312
DO - 10.3201/eid2408.171312
M3 - Article
C2 - 30016256
AN - SCOPUS:85050384089
SN - 1080-6040
VL - 24
SP - e1-e13
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 8
ER -
